30 completed, 12 terminated, 11 active not recruiting, 11 recruiting. 56 Phase 2, 23 Phase 1, 4 Phase 3, 3 Not applicable, 2 Early Phase 1.
Follow Thyroid Carcinoma, Anaplastic: new trials by email Literature Review of Thyroid Carcinoma, Anaplastic trials Research Report on Thyroid Carcinoma, Anaplastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer Cemiplimab, Zanzalintinib - Anaplastic Thyroid Cancer | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 12 | 2027-01-31 | 2026-10-14 |
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial Personalised treatment - Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer | Phase 1 | Recruiting | Radboud University Medical Center | 10 | 2026-10-01 | 2026-10-28 |
| Selective Coverage Versus Comprehensive Coverage Radiotherapy in Poorly Differentiated and Anaplastic Thyroid Cancer Selective coverage radiotherapy, comprehensive coverage radiotherapy - Thyroid Cancer | Phase 2 | Recruiting | Fudan University | 72 | 2026-08-12 | 2026-08-20 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| [177Lu]Lu-AKIR001 First-in-human Study [177Lu]Lu-AKIR001 - Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma | Early Phase 1 | Recruiting | Karolinska University Hospital | 15 | 2026-01-28 | 2026-01-30 |
| IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 - Peritoneal Mesothelioma, Gestational Trophoblastic Tumor | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 27 | 2025-10-01 | 2026-06-25 |
| CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors CD70-targeted CAR-T cells - Renal Cell Carcinoma (RCC), Lung Cancer | Phase 1 | Suspended | Chongqing Precision Biotech Co., Ltd | 90 | 2025-09-12 | 2026-09-11 |
| Taiwanese Anaplastic Thyroid Cancer Registry Thyroid Carcinoma, Anaplastic | Not yet recruiting | National Health Research Institutes, Taiwan | 100 | 2025-09-01 | 2025-08-22 | |
| Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer Sacituzumab Tirumotecan (SKB264) plus Tislelizumab, Sacituzumab Tirumotecan (SKB264) - Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer | Not applicable | Recruiting | Zhejiang Provincial People's Hospital | 94 | 2025-07-01 | 2026-06-01 |
| XL092 and Cemiplimab in BRAF WT Thyroid Cancer Cemiplimab, XL092 - Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2025-06-03 | 2026-10-05 |
| Sacituzumab govitEcan in THYroid Cancers Sacituzumab govitecan - Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer | Phase 2 | Recruiting | Grupo Espanol de Tumores Neuroendocrinos | 42 | 2024-09-13 | 2026-09-16 |
| Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences Anaplastic Thyroid Cancer | Unknown | Power Life Sciences Inc. | 500 | 2024-05-01 | 2023-04-19 | |
| Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer Pembrolizumab + Lenvatinib - Anaplastic Thyroid Cancer | Phase 2 | Recruiting | Saint Petersburg State University, Russia | 20 | 2024-03-25 | 2025-09-05 |
| Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Dabrafenib + Trametinib - Anaplastic Thyroid Cancer | Phase 2 | Unknown | Saint Petersburg State University, Russia | 10 | 2024-03-25 | 2024-04-12 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations Plixorafenib - Cancer Harboring BRAF Alterations, HGG | Phase 2 | Recruiting | Fore Biotherapeutics | 254 | 2023-02-21 | 2026-07-27 |
| NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) dabrafenib/trametinib - Anaplastic Thyroid Cancer | Phase 2 | Recruiting | Leiden University Medical Center | 20 | 2023-01-01 | 2023-10-12 |
| European Multicenter Study on Surgical Management of Advanced Thyroid Cancer Thyroidectomy with or without lymphadenectomy or multivisceral resection - Thyroid Carcinoma, Thyroid Cancer | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 3917 | 2022-12-15 | 2023-04-04 |
Showing 20 of 87. Sign in to see all of them.
Thyroid Neoplasms (40) · Carcinoma, Medullary (19) · Thyroid Cancer, Papillary (18) · Head and Neck Neoplasms (16) · Adenocarcinoma, Follicular (15) · Carcinoma, Non-Small-Cell Lung (12) · Colorectal Neoplasms (8) · Salivary Gland Neoplasms (8) · Melanoma (7) · Neoplasms (7) · Squamous Cell Carcinoma of Head and Neck (7) · Carcinoma, Hepatocellular (6) · Colonic Neoplasms (6) · Breast Neoplasms (5)
Neoplasms, Glandular and Epithelial (87) · Carcinoma (86) · Neoplasms by Histologic Type (85) · Neoplasms (80) · Neoplasms by Site (53) · Endocrine Gland Neoplasms (46) · Endocrine System Diseases (46) · Thyroid Diseases (42) · Neoplasms, Germ Cell and Embryonal (31) · Neoplasms, Nerve Tissue (31) · Neuroectodermal Tumors (31) · Head and Neck Neoplasms (30) · Adenocarcinoma (27) · Neuroendocrine Tumors (26) · Carcinoma, Neuroendocrine (19)
Paclitaxel (10) · dabrafenib (10) · trametinib (10) · pembrolizumab (6) · lenvatinib (5) · Doxorubicin (4) · Radiotherapy, Intensity-Modulated (4) · Sorafenib (4) · fosbretabulin (4) · Cisplatin (3) · Radiotherapy (3) · Bevacizumab (2) · Carboplatin (2) · Docetaxel (2) · Everolimus (2)
National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (6) · Case Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Saint Petersburg State University, Russia (3) · Cancer Research UK (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Fore Biotherapeutics (2) · Grupo Espanol de Tumores Neuroendocrinos (2) · Leiden University Medical Center (2) · Mateon Therapeutics (2) · National Taiwan University Hospital (2) · Northwestern University (2) · Novartis Pharmaceuticals (2) · AffyImmune Therapeutics, Inc. (1)
United States (50) · China (7) · Italy (7) · Netherlands (7) · France (6) · Germany (6) · United Kingdom (6) · Canada (5) · Spain (5) · Russia (4) · Sweden (4) · Taiwan (4) · Australia (3) · Japan (3) · Norway (3)
Ellen Kapiteijn, MD, PhD (2) · Eric Sherman, MD (2) · Maria E Cabanillas (2) · Mark Zafereo (2) · Panayiotis Savvides, MD (2) · Saad A Khan, MD (2) · Amir A Jazaeri (1) · Anthony W. Tolcher, MD (1) · Ashish Chintakuntlawar (1) · Barry L. Gause, MD (1) · Byung Chul Cho (1) · Cornelis J. A. Punt, MD, PhD (1)
PMID 27240885, PMID 32612576, PMID 37816266, PMID 17985341, PMID 17985985, PMID 19265494, PMID 19372041, PMID 19602035, PMID 19735988, PMID 20145168, PMID 20851682, PMID 21367608, PMID 23113752, PMID 24050953, PMID 25092772, PMID 27169792, PMID 29020892, PMID 29072975, PMID 29192093, PMID 32179633, PMID 32364844, PMID 32475305, PMID 32538690, PMID 32818466, PMID 33720068, PMID 33961488, PMID 34541894, PMID 34838156, PMID 35521657, PMID 36108341, PMID 36681089, PMID 36795619, PMID 37059834, PMID 37219859, PMID 37934000, PMID 38803995, PMID 39446377, PMID 41198237, PMID 42673705
2023 (3), P30CA043703 (3), 2014 (2), P30CA015083 (2), P30CA060553 (2), U01CA062502 (2), U01CA076576 (2), 2015 (1), 2019 (1), N01CM00099 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1), P30CA006516 (1), P30CA016058 (1)